MedTrace Logo

Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback

NCT06873841 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-07-08

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults.

Hypotheses:

1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone.
2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics.

Researchers will compare if the biofeedback treatment will improve the severity of tics.

* In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted.
* They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section).
* The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.

Conditions

  • Tourette Syndrome
  • Tics
  • Tourette Syndrome in Adolescence

Interventions

BEHAVIORAL

Cognitive psychophysiological

Focus on the processes influencing thoughts and behaviors underlying tics.

BEHAVIORAL

Cognitive psychophysiological and Biofeedback

Biofeedback refers to visual exercises that help improve movement control.

Sponsors & Collaborators

  • Ciusss de L'Est de l'Île de Montréal

    collaborator OTHER

  • Université du Québec a Montréal

    lead OTHER

Principal Investigators

  • Julie Leclerc, Psychology · Université du Québec à Montréal- UQAM

  • Marc Lavoie, Psychology · Université TÉLUQ

  • Marie-France Marin, Psychology · Université du Québec à Montréal-UQAM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06873841 on ClinicalTrials.gov